SKOKIE, Ill.--(BUSINESS WIRE)--Apr. 30, 2019--
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced a poster presentation at ARVO 2019 Annual Meeting
in Vancouver, British Columbia. The poster is titled “Spherical Nucleic
Acids Exhibit Enhanced Distribution and Persistence Compared to Linear
Oligonucleotides in Rat Eyes Following Intravitreal Administration” and
will be presented by Bart Anderson, Director of R&D at Exicure.
Session Date/Times: Tuesday, April 30, 2019 from 11:45 am to 1:30 pm PDT
and 4:30 pm to 5:30 pm PDT
Presentation number: 3378, Poster board number A0148
Session track: Drug delivery, drug and gene delivery system, implant
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure's proprietary SNA architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL.www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005078/en/
Source: Exicure, Inc.